Heart disease patients more apt to take one combined pill than many | Science News



Support credible science journalism.

Subscribe to Science News today.

News in Brief

Heart disease patients more apt to take one combined pill than many

People stayed on top of their medications better with a 'polypill'

4:35pm, September 3, 2013
Sponsor Message

A single pill that combines medicines to tone down blood pressure, cholesterol and blood clotting improves the likelihood that patients will take their meds. The “polypill” might boost the health of people who otherwise might skip taking pills, researchers report in the Sept. 4 JAMA.

For patients who must manage a bagful of heart meds, the polypill sounds great. But the concept had previously undergone only limited testing. In the study, 2,004 people in Europe and India who had heart disease or were at risk of developing it were randomly assigned to get standard pills for the three conditions or a daily polypill.

The polypill included aspirin for blood clots, simvastatin (Zocor) for high cholesterol and two blood pressure medications. Over 15 months, 86 percent of the people assigned to get the polypill kept up with their medications while only 65 percent of the others did. In people who had previously had trouble taking their pills regularly, the polypill provided a sharp improvement – 77 percent instead of 23 percent took their medicines.

Overall, the polypill group also had slight declines in systolic blood pressure and LDL cholesterol compared to those getting pills piecemeal.


S. Thom et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE Randomized Clinical Trial. JAMA. Volume 310, Sept. 4, 2013, p. 918. doi: 10.1001/jama.2013.277064. [Go to]
Further Reading

E. Lonn et al. The Polypill in the Prevention of Cardiovascular Diseases Key Concepts, Current Status, Challenges, and Future Directions. Circulation. Volume122, Aug. 27, 2010, p. 2078. doi: 10.1161/​CIRCULATIONAHA.109.873232. [Go to]

S. Yusuf et al. Indian Polycap Study. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. Volume 373, April 18, 2009, p. 1341. doi: 10.1016/S0140-6736(09)60611-5. [Go to]

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content